nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—CYP2C19—prostate cancer	0.163	0.611	CbGaD
Levomilnacipran—CYP3A4—prostate cancer	0.104	0.389	CbGaD
Levomilnacipran—CYP2C8—Nilutamide—prostate cancer	0.0317	0.0685	CbGbCtD
Levomilnacipran—CYP2C19—Nilutamide—prostate cancer	0.0266	0.0575	CbGbCtD
Levomilnacipran—CYP2C19—Bicalutamide—prostate cancer	0.0266	0.0575	CbGbCtD
Levomilnacipran—CYP2C8—Abiraterone—prostate cancer	0.0262	0.0568	CbGbCtD
Levomilnacipran—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0244	0.0529	CbGbCtD
Levomilnacipran—CYP2C19—Flutamide—prostate cancer	0.022	0.0476	CbGbCtD
Levomilnacipran—CYP2D6—Bicalutamide—prostate cancer	0.0202	0.0437	CbGbCtD
Levomilnacipran—ABCB1—Estramustine—prostate cancer	0.0199	0.0431	CbGbCtD
Levomilnacipran—CYP2C8—Cabazitaxel—prostate cancer	0.0194	0.042	CbGbCtD
Levomilnacipran—CYP2C8—Ethinyl Estradiol—prostate cancer	0.0169	0.0366	CbGbCtD
Levomilnacipran—CYP2D6—Abiraterone—prostate cancer	0.0167	0.0362	CbGbCtD
Levomilnacipran—ABCB1—Cabazitaxel—prostate cancer	0.0131	0.0284	CbGbCtD
Levomilnacipran—CYP3A4—Bicalutamide—prostate cancer	0.0128	0.0278	CbGbCtD
Levomilnacipran—ABCB1—Estrone—prostate cancer	0.0128	0.0278	CbGbCtD
Levomilnacipran—CYP3A4—Estramustine—prostate cancer	0.0119	0.0258	CbGbCtD
Levomilnacipran—ABCB1—Ethinyl Estradiol—prostate cancer	0.0114	0.0248	CbGbCtD
Levomilnacipran—CYP2C8—Estradiol—prostate cancer	0.0109	0.0236	CbGbCtD
Levomilnacipran—CYP3A4—Abiraterone—prostate cancer	0.0106	0.023	CbGbCtD
Levomilnacipran—CYP3A4—Flutamide—prostate cancer	0.0106	0.023	CbGbCtD
Levomilnacipran—CYP2C19—Estradiol—prostate cancer	0.00914	0.0198	CbGbCtD
Levomilnacipran—ABCB1—Conjugated Estrogens—prostate cancer	0.0084	0.0182	CbGbCtD
Levomilnacipran—CYP3A4—Cabazitaxel—prostate cancer	0.00787	0.017	CbGbCtD
Levomilnacipran—CYP2C19—Prednisone—prostate cancer	0.00786	0.017	CbGbCtD
Levomilnacipran—CYP3A4—Estrone—prostate cancer	0.00769	0.0166	CbGbCtD
Levomilnacipran—ABCB1—Mitoxantrone—prostate cancer	0.00763	0.0165	CbGbCtD
Levomilnacipran—ABCB1—Estradiol—prostate cancer	0.00737	0.016	CbGbCtD
Levomilnacipran—CYP2C8—Etoposide—prostate cancer	0.00711	0.0154	CbGbCtD
Levomilnacipran—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00686	0.0148	CbGbCtD
Levomilnacipran—ABCB1—Prednisone—prostate cancer	0.00634	0.0137	CbGbCtD
Levomilnacipran—CYP3A4—Conjugated Estrogens—prostate cancer	0.00503	0.0109	CbGbCtD
Levomilnacipran—ABCB1—Etoposide—prostate cancer	0.00481	0.0104	CbGbCtD
Levomilnacipran—CYP3A4—Mitoxantrone—prostate cancer	0.00457	0.0099	CbGbCtD
Levomilnacipran—CYP3A4—Estradiol—prostate cancer	0.00442	0.00956	CbGbCtD
Levomilnacipran—ABCB1—Docetaxel—prostate cancer	0.0044	0.00953	CbGbCtD
Levomilnacipran—CYP3A4—Prednisone—prostate cancer	0.0038	0.00822	CbGbCtD
Levomilnacipran—ABCB1—Doxorubicin—prostate cancer	0.00328	0.0071	CbGbCtD
Levomilnacipran—CYP2D6—Doxorubicin—prostate cancer	0.00309	0.00669	CbGbCtD
Levomilnacipran—CYP3A4—Etoposide—prostate cancer	0.00288	0.00624	CbGbCtD
Levomilnacipran—CYP3A4—Docetaxel—prostate cancer	0.00264	0.00571	CbGbCtD
Levomilnacipran—CYP3A4—Doxorubicin—prostate cancer	0.00197	0.00426	CbGbCtD
Levomilnacipran—CYP2C19—urine—prostate cancer	0.000879	0.195	CbGeAlD
Levomilnacipran—CYP2J2—prostate gland—prostate cancer	0.000706	0.157	CbGeAlD
Levomilnacipran—CYP3A4—urine—prostate cancer	0.00052	0.115	CbGeAlD
Levomilnacipran—CYP2D6—urine—prostate cancer	0.000511	0.113	CbGeAlD
Levomilnacipran—CYP2J2—testis—prostate cancer	0.000311	0.0689	CbGeAlD
Levomilnacipran—CYP2C8—renal system—prostate cancer	0.000188	0.0416	CbGeAlD
Levomilnacipran—SLC6A2—testis—prostate cancer	0.000148	0.0327	CbGeAlD
Levomilnacipran—ABCB1—prostate gland—prostate cancer	0.000132	0.0293	CbGeAlD
Levomilnacipran—CYP3A4—renal system—prostate cancer	0.000127	0.0282	CbGeAlD
Levomilnacipran—CYP2D6—renal system—prostate cancer	0.000125	0.0277	CbGeAlD
Levomilnacipran—CYP2C8—testis—prostate cancer	0.000121	0.0269	CbGeAlD
Levomilnacipran—ABCB1—seminal vesicle—prostate cancer	0.000112	0.0247	CbGeAlD
Levomilnacipran—SLC6A2—lymph node—prostate cancer	0.000107	0.0237	CbGeAlD
Levomilnacipran—ABCB1—epithelium—prostate cancer	9.7e-05	0.0215	CbGeAlD
Levomilnacipran—ABCB1—renal system—prostate cancer	9e-05	0.0199	CbGeAlD
Levomilnacipran—ABCB1—urethra—prostate cancer	8.84e-05	0.0196	CbGeAlD
Levomilnacipran—CYP2D6—testis—prostate cancer	8.09e-05	0.0179	CbGeAlD
Levomilnacipran—ABCB1—bone marrow—prostate cancer	6.81e-05	0.0151	CbGeAlD
Levomilnacipran—ABCB1—testis—prostate cancer	5.82e-05	0.0129	CbGeAlD
Levomilnacipran—Infection—Docetaxel—prostate cancer	5.12e-05	0.00032	CcSEcCtD
Levomilnacipran—Weight decreased—Doxorubicin—prostate cancer	5.12e-05	0.00032	CcSEcCtD
Levomilnacipran—Diarrhoea—Mitoxantrone—prostate cancer	5.1e-05	0.000318	CcSEcCtD
Levomilnacipran—Dry mouth—Capecitabine—prostate cancer	5.09e-05	0.000318	CcSEcCtD
Levomilnacipran—Vomiting—Estradiol—prostate cancer	5.09e-05	0.000318	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Etoposide—prostate cancer	5.07e-05	0.000317	CcSEcCtD
Levomilnacipran—Shock—Docetaxel—prostate cancer	5.07e-05	0.000317	CcSEcCtD
Levomilnacipran—Nervous system disorder—Docetaxel—prostate cancer	5.06e-05	0.000316	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Docetaxel—prostate cancer	5.05e-05	0.000315	CcSEcCtD
Levomilnacipran—Rash—Estradiol—prostate cancer	5.05e-05	0.000315	CcSEcCtD
Levomilnacipran—Dermatitis—Estradiol—prostate cancer	5.04e-05	0.000315	CcSEcCtD
Levomilnacipran—Tachycardia—Docetaxel—prostate cancer	5.03e-05	0.000314	CcSEcCtD
Levomilnacipran—Headache—Estradiol—prostate cancer	5.01e-05	0.000313	CcSEcCtD
Levomilnacipran—Skin disorder—Docetaxel—prostate cancer	5.01e-05	0.000313	CcSEcCtD
Levomilnacipran—Agitation—Prednisone—prostate cancer	5.01e-05	0.000312	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	5e-05	0.000312	CcSEcCtD
Levomilnacipran—Infection—Capecitabine—prostate cancer	4.96e-05	0.00031	CcSEcCtD
Levomilnacipran—Urticaria—Etoposide—prostate cancer	4.93e-05	0.000308	CcSEcCtD
Levomilnacipran—Anorexia—Docetaxel—prostate cancer	4.91e-05	0.000307	CcSEcCtD
Levomilnacipran—Shock—Capecitabine—prostate cancer	4.91e-05	0.000307	CcSEcCtD
Levomilnacipran—Abdominal pain—Etoposide—prostate cancer	4.9e-05	0.000306	CcSEcCtD
Levomilnacipran—Body temperature increased—Etoposide—prostate cancer	4.9e-05	0.000306	CcSEcCtD
Levomilnacipran—Urinary tract infection—Doxorubicin—prostate cancer	4.9e-05	0.000306	CcSEcCtD
Levomilnacipran—Nervous system disorder—Capecitabine—prostate cancer	4.9e-05	0.000306	CcSEcCtD
Levomilnacipran—Hepatitis—Epirubicin—prostate cancer	4.89e-05	0.000305	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Capecitabine—prostate cancer	4.89e-05	0.000305	CcSEcCtD
Levomilnacipran—Syncope—Prednisone—prostate cancer	4.89e-05	0.000305	CcSEcCtD
Levomilnacipran—Tachycardia—Capecitabine—prostate cancer	4.87e-05	0.000304	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Epirubicin—prostate cancer	4.87e-05	0.000304	CcSEcCtD
Levomilnacipran—Skin disorder—Capecitabine—prostate cancer	4.85e-05	0.000303	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Epirubicin—prostate cancer	4.83e-05	0.000302	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Capecitabine—prostate cancer	4.83e-05	0.000301	CcSEcCtD
Levomilnacipran—Oedema peripheral—Epirubicin—prostate cancer	4.82e-05	0.000301	CcSEcCtD
Levomilnacipran—Hypotension—Docetaxel—prostate cancer	4.82e-05	0.000301	CcSEcCtD
Levomilnacipran—Haematuria—Doxorubicin—prostate cancer	4.81e-05	0.0003	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Epirubicin—prostate cancer	4.81e-05	0.0003	CcSEcCtD
Levomilnacipran—Urethral disorder—Epirubicin—prostate cancer	4.8e-05	0.000299	CcSEcCtD
Levomilnacipran—Loss of consciousness—Prednisone—prostate cancer	4.79e-05	0.000299	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Doxorubicin—prostate cancer	4.77e-05	0.000298	CcSEcCtD
Levomilnacipran—Anorexia—Capecitabine—prostate cancer	4.76e-05	0.000297	CcSEcCtD
Levomilnacipran—Nausea—Estradiol—prostate cancer	4.75e-05	0.000297	CcSEcCtD
Levomilnacipran—Vomiting—Mitoxantrone—prostate cancer	4.74e-05	0.000296	CcSEcCtD
Levomilnacipran—Convulsion—Prednisone—prostate cancer	4.72e-05	0.000295	CcSEcCtD
Levomilnacipran—Hypertension—Prednisone—prostate cancer	4.7e-05	0.000294	CcSEcCtD
Levomilnacipran—Rash—Mitoxantrone—prostate cancer	4.7e-05	0.000294	CcSEcCtD
Levomilnacipran—Dermatitis—Mitoxantrone—prostate cancer	4.7e-05	0.000293	CcSEcCtD
Levomilnacipran—Headache—Mitoxantrone—prostate cancer	4.67e-05	0.000292	CcSEcCtD
Levomilnacipran—Hypotension—Capecitabine—prostate cancer	4.66e-05	0.000291	CcSEcCtD
Levomilnacipran—Insomnia—Docetaxel—prostate cancer	4.66e-05	0.000291	CcSEcCtD
Levomilnacipran—Paraesthesia—Docetaxel—prostate cancer	4.63e-05	0.000289	CcSEcCtD
Levomilnacipran—Erythema multiforme—Epirubicin—prostate cancer	4.63e-05	0.000289	CcSEcCtD
Levomilnacipran—Anxiety—Prednisone—prostate cancer	4.62e-05	0.000288	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	4.61e-05	0.000287	CcSEcCtD
Levomilnacipran—Dyspnoea—Docetaxel—prostate cancer	4.6e-05	0.000287	CcSEcCtD
Levomilnacipran—Somnolence—Docetaxel—prostate cancer	4.58e-05	0.000286	CcSEcCtD
Levomilnacipran—Eye disorder—Epirubicin—prostate cancer	4.57e-05	0.000285	CcSEcCtD
Levomilnacipran—Hypersensitivity—Etoposide—prostate cancer	4.57e-05	0.000285	CcSEcCtD
Levomilnacipran—Flushing—Epirubicin—prostate cancer	4.54e-05	0.000284	CcSEcCtD
Levomilnacipran—Cardiac disorder—Epirubicin—prostate cancer	4.54e-05	0.000284	CcSEcCtD
Levomilnacipran—Dyspepsia—Docetaxel—prostate cancer	4.54e-05	0.000283	CcSEcCtD
Levomilnacipran—Hepatitis—Doxorubicin—prostate cancer	4.53e-05	0.000283	CcSEcCtD
Levomilnacipran—Insomnia—Capecitabine—prostate cancer	4.51e-05	0.000282	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Doxorubicin—prostate cancer	4.51e-05	0.000281	CcSEcCtD
Levomilnacipran—Paraesthesia—Capecitabine—prostate cancer	4.48e-05	0.00028	CcSEcCtD
Levomilnacipran—Decreased appetite—Docetaxel—prostate cancer	4.48e-05	0.00028	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Doxorubicin—prostate cancer	4.47e-05	0.000279	CcSEcCtD
Levomilnacipran—Oedema peripheral—Doxorubicin—prostate cancer	4.46e-05	0.000278	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Docetaxel—prostate cancer	4.45e-05	0.000278	CcSEcCtD
Levomilnacipran—Asthenia—Etoposide—prostate cancer	4.45e-05	0.000278	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Doxorubicin—prostate cancer	4.45e-05	0.000278	CcSEcCtD
Levomilnacipran—Dyspnoea—Capecitabine—prostate cancer	4.45e-05	0.000278	CcSEcCtD
Levomilnacipran—Fatigue—Docetaxel—prostate cancer	4.45e-05	0.000277	CcSEcCtD
Levomilnacipran—Angiopathy—Epirubicin—prostate cancer	4.44e-05	0.000277	CcSEcCtD
Levomilnacipran—Urethral disorder—Doxorubicin—prostate cancer	4.44e-05	0.000277	CcSEcCtD
Levomilnacipran—Nausea—Mitoxantrone—prostate cancer	4.43e-05	0.000276	CcSEcCtD
Levomilnacipran—Infection—Prednisone—prostate cancer	4.42e-05	0.000276	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Epirubicin—prostate cancer	4.41e-05	0.000275	CcSEcCtD
Levomilnacipran—Constipation—Docetaxel—prostate cancer	4.41e-05	0.000275	CcSEcCtD
Levomilnacipran—Dyspepsia—Capecitabine—prostate cancer	4.39e-05	0.000274	CcSEcCtD
Levomilnacipran—Chills—Epirubicin—prostate cancer	4.39e-05	0.000274	CcSEcCtD
Levomilnacipran—Pruritus—Etoposide—prostate cancer	4.39e-05	0.000274	CcSEcCtD
Levomilnacipran—Shock—Prednisone—prostate cancer	4.37e-05	0.000273	CcSEcCtD
Levomilnacipran—Nervous system disorder—Prednisone—prostate cancer	4.36e-05	0.000272	CcSEcCtD
Levomilnacipran—Tachycardia—Prednisone—prostate cancer	4.34e-05	0.000271	CcSEcCtD
Levomilnacipran—Decreased appetite—Capecitabine—prostate cancer	4.34e-05	0.000271	CcSEcCtD
Levomilnacipran—Skin disorder—Prednisone—prostate cancer	4.32e-05	0.00027	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Capecitabine—prostate cancer	4.31e-05	0.000269	CcSEcCtD
Levomilnacipran—Fatigue—Capecitabine—prostate cancer	4.3e-05	0.000269	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Prednisone—prostate cancer	4.3e-05	0.000268	CcSEcCtD
Levomilnacipran—Mental disorder—Epirubicin—prostate cancer	4.29e-05	0.000268	CcSEcCtD
Levomilnacipran—Erythema multiforme—Doxorubicin—prostate cancer	4.28e-05	0.000267	CcSEcCtD
Levomilnacipran—Constipation—Capecitabine—prostate cancer	4.27e-05	0.000266	CcSEcCtD
Levomilnacipran—Malnutrition—Epirubicin—prostate cancer	4.26e-05	0.000266	CcSEcCtD
Levomilnacipran—Diarrhoea—Etoposide—prostate cancer	4.24e-05	0.000265	CcSEcCtD
Levomilnacipran—Anorexia—Prednisone—prostate cancer	4.24e-05	0.000265	CcSEcCtD
Levomilnacipran—Eye disorder—Doxorubicin—prostate cancer	4.23e-05	0.000264	CcSEcCtD
Levomilnacipran—ABCB1—lymph node—prostate cancer	4.22e-05	0.00934	CbGeAlD
Levomilnacipran—Gastrointestinal pain—Docetaxel—prostate cancer	4.22e-05	0.000263	CcSEcCtD
Levomilnacipran—Flushing—Doxorubicin—prostate cancer	4.2e-05	0.000262	CcSEcCtD
Levomilnacipran—Cardiac disorder—Doxorubicin—prostate cancer	4.2e-05	0.000262	CcSEcCtD
Levomilnacipran—Flatulence—Epirubicin—prostate cancer	4.2e-05	0.000262	CcSEcCtD
Levomilnacipran—Tension—Epirubicin—prostate cancer	4.18e-05	0.000261	CcSEcCtD
Levomilnacipran—Dysgeusia—Epirubicin—prostate cancer	4.17e-05	0.00026	CcSEcCtD
Levomilnacipran—Angiopathy—Doxorubicin—prostate cancer	4.11e-05	0.000256	CcSEcCtD
Levomilnacipran—Dizziness—Etoposide—prostate cancer	4.1e-05	0.000256	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Capecitabine—prostate cancer	4.08e-05	0.000255	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Doxorubicin—prostate cancer	4.08e-05	0.000255	CcSEcCtD
Levomilnacipran—Abdominal pain—Docetaxel—prostate cancer	4.08e-05	0.000254	CcSEcCtD
Levomilnacipran—Body temperature increased—Docetaxel—prostate cancer	4.08e-05	0.000254	CcSEcCtD
Levomilnacipran—Chills—Doxorubicin—prostate cancer	4.06e-05	0.000254	CcSEcCtD
Levomilnacipran—Insomnia—Prednisone—prostate cancer	4.02e-05	0.000251	CcSEcCtD
Levomilnacipran—Vision blurred—Epirubicin—prostate cancer	4.02e-05	0.000251	CcSEcCtD
Levomilnacipran—Paraesthesia—Prednisone—prostate cancer	3.99e-05	0.000249	CcSEcCtD
Levomilnacipran—Mental disorder—Doxorubicin—prostate cancer	3.97e-05	0.000248	CcSEcCtD
Levomilnacipran—Urticaria—Capecitabine—prostate cancer	3.97e-05	0.000247	CcSEcCtD
Levomilnacipran—Body temperature increased—Capecitabine—prostate cancer	3.95e-05	0.000246	CcSEcCtD
Levomilnacipran—Abdominal pain—Capecitabine—prostate cancer	3.95e-05	0.000246	CcSEcCtD
Levomilnacipran—Vomiting—Etoposide—prostate cancer	3.94e-05	0.000246	CcSEcCtD
Levomilnacipran—Malnutrition—Doxorubicin—prostate cancer	3.94e-05	0.000246	CcSEcCtD
Levomilnacipran—Agitation—Epirubicin—prostate cancer	3.92e-05	0.000244	CcSEcCtD
Levomilnacipran—Dyspepsia—Prednisone—prostate cancer	3.91e-05	0.000244	CcSEcCtD
Levomilnacipran—Rash—Etoposide—prostate cancer	3.91e-05	0.000244	CcSEcCtD
Levomilnacipran—Dermatitis—Etoposide—prostate cancer	3.91e-05	0.000244	CcSEcCtD
Levomilnacipran—Headache—Etoposide—prostate cancer	3.89e-05	0.000243	CcSEcCtD
Levomilnacipran—Flatulence—Doxorubicin—prostate cancer	3.89e-05	0.000242	CcSEcCtD
Levomilnacipran—Tension—Doxorubicin—prostate cancer	3.87e-05	0.000241	CcSEcCtD
Levomilnacipran—Decreased appetite—Prednisone—prostate cancer	3.87e-05	0.000241	CcSEcCtD
Levomilnacipran—Dysgeusia—Doxorubicin—prostate cancer	3.86e-05	0.000241	CcSEcCtD
Levomilnacipran—Fatigue—Prednisone—prostate cancer	3.83e-05	0.000239	CcSEcCtD
Levomilnacipran—Syncope—Epirubicin—prostate cancer	3.82e-05	0.000238	CcSEcCtD
Levomilnacipran—Leukopenia—Epirubicin—prostate cancer	3.81e-05	0.000238	CcSEcCtD
Levomilnacipran—Constipation—Prednisone—prostate cancer	3.8e-05	0.000237	CcSEcCtD
Levomilnacipran—Hypersensitivity—Docetaxel—prostate cancer	3.8e-05	0.000237	CcSEcCtD
Levomilnacipran—Palpitations—Epirubicin—prostate cancer	3.77e-05	0.000235	CcSEcCtD
Levomilnacipran—Loss of consciousness—Epirubicin—prostate cancer	3.75e-05	0.000234	CcSEcCtD
Levomilnacipran—Vision blurred—Doxorubicin—prostate cancer	3.72e-05	0.000232	CcSEcCtD
Levomilnacipran—Asthenia—Docetaxel—prostate cancer	3.7e-05	0.000231	CcSEcCtD
Levomilnacipran—Convulsion—Epirubicin—prostate cancer	3.69e-05	0.00023	CcSEcCtD
Levomilnacipran—Nausea—Etoposide—prostate cancer	3.69e-05	0.00023	CcSEcCtD
Levomilnacipran—Hypertension—Epirubicin—prostate cancer	3.68e-05	0.00023	CcSEcCtD
Levomilnacipran—Hypersensitivity—Capecitabine—prostate cancer	3.68e-05	0.00023	CcSEcCtD
Levomilnacipran—Pruritus—Docetaxel—prostate cancer	3.65e-05	0.000228	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Prednisone—prostate cancer	3.64e-05	0.000227	CcSEcCtD
Levomilnacipran—Chest pain—Epirubicin—prostate cancer	3.63e-05	0.000226	CcSEcCtD
Levomilnacipran—Agitation—Doxorubicin—prostate cancer	3.62e-05	0.000226	CcSEcCtD
Levomilnacipran—Anxiety—Epirubicin—prostate cancer	3.62e-05	0.000226	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.6e-05	0.000225	CcSEcCtD
Levomilnacipran—Asthenia—Capecitabine—prostate cancer	3.58e-05	0.000224	CcSEcCtD
Levomilnacipran—Dry mouth—Epirubicin—prostate cancer	3.55e-05	0.000221	CcSEcCtD
Levomilnacipran—Syncope—Doxorubicin—prostate cancer	3.54e-05	0.000221	CcSEcCtD
Levomilnacipran—Urticaria—Prednisone—prostate cancer	3.53e-05	0.00022	CcSEcCtD
Levomilnacipran—Pruritus—Capecitabine—prostate cancer	3.53e-05	0.00022	CcSEcCtD
Levomilnacipran—Leukopenia—Doxorubicin—prostate cancer	3.53e-05	0.00022	CcSEcCtD
Levomilnacipran—Diarrhoea—Docetaxel—prostate cancer	3.53e-05	0.00022	CcSEcCtD
Levomilnacipran—Body temperature increased—Prednisone—prostate cancer	3.51e-05	0.000219	CcSEcCtD
Levomilnacipran—Abdominal pain—Prednisone—prostate cancer	3.51e-05	0.000219	CcSEcCtD
Levomilnacipran—Palpitations—Doxorubicin—prostate cancer	3.48e-05	0.000217	CcSEcCtD
Levomilnacipran—Loss of consciousness—Doxorubicin—prostate cancer	3.47e-05	0.000216	CcSEcCtD
Levomilnacipran—Infection—Epirubicin—prostate cancer	3.45e-05	0.000216	CcSEcCtD
Levomilnacipran—Shock—Epirubicin—prostate cancer	3.42e-05	0.000214	CcSEcCtD
Levomilnacipran—Convulsion—Doxorubicin—prostate cancer	3.42e-05	0.000213	CcSEcCtD
Levomilnacipran—Diarrhoea—Capecitabine—prostate cancer	3.42e-05	0.000213	CcSEcCtD
Levomilnacipran—Nervous system disorder—Epirubicin—prostate cancer	3.41e-05	0.000213	CcSEcCtD
Levomilnacipran—Dizziness—Docetaxel—prostate cancer	3.41e-05	0.000213	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Epirubicin—prostate cancer	3.4e-05	0.000213	CcSEcCtD
Levomilnacipran—Hypertension—Doxorubicin—prostate cancer	3.4e-05	0.000212	CcSEcCtD
Levomilnacipran—Tachycardia—Epirubicin—prostate cancer	3.39e-05	0.000212	CcSEcCtD
Levomilnacipran—Skin disorder—Epirubicin—prostate cancer	3.38e-05	0.000211	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Epirubicin—prostate cancer	3.36e-05	0.00021	CcSEcCtD
Levomilnacipran—Chest pain—Doxorubicin—prostate cancer	3.36e-05	0.000209	CcSEcCtD
Levomilnacipran—Anxiety—Doxorubicin—prostate cancer	3.34e-05	0.000209	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	3.33e-05	0.000208	CcSEcCtD
Levomilnacipran—Anorexia—Epirubicin—prostate cancer	3.31e-05	0.000207	CcSEcCtD
Levomilnacipran—Dizziness—Capecitabine—prostate cancer	3.3e-05	0.000206	CcSEcCtD
Levomilnacipran—Dry mouth—Doxorubicin—prostate cancer	3.28e-05	0.000205	CcSEcCtD
Levomilnacipran—Vomiting—Docetaxel—prostate cancer	3.28e-05	0.000205	CcSEcCtD
Levomilnacipran—Hypersensitivity—Prednisone—prostate cancer	3.28e-05	0.000204	CcSEcCtD
Levomilnacipran—Rash—Docetaxel—prostate cancer	3.25e-05	0.000203	CcSEcCtD
Levomilnacipran—Hypotension—Epirubicin—prostate cancer	3.25e-05	0.000203	CcSEcCtD
Levomilnacipran—Dermatitis—Docetaxel—prostate cancer	3.25e-05	0.000203	CcSEcCtD
Levomilnacipran—Headache—Docetaxel—prostate cancer	3.23e-05	0.000202	CcSEcCtD
Levomilnacipran—Infection—Doxorubicin—prostate cancer	3.2e-05	0.0002	CcSEcCtD
Levomilnacipran—Asthenia—Prednisone—prostate cancer	3.19e-05	0.000199	CcSEcCtD
Levomilnacipran—Vomiting—Capecitabine—prostate cancer	3.17e-05	0.000198	CcSEcCtD
Levomilnacipran—Shock—Doxorubicin—prostate cancer	3.17e-05	0.000198	CcSEcCtD
Levomilnacipran—Nervous system disorder—Doxorubicin—prostate cancer	3.16e-05	0.000197	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Doxorubicin—prostate cancer	3.15e-05	0.000197	CcSEcCtD
Levomilnacipran—Rash—Capecitabine—prostate cancer	3.15e-05	0.000196	CcSEcCtD
Levomilnacipran—Pruritus—Prednisone—prostate cancer	3.15e-05	0.000196	CcSEcCtD
Levomilnacipran—Insomnia—Epirubicin—prostate cancer	3.15e-05	0.000196	CcSEcCtD
Levomilnacipran—Dermatitis—Capecitabine—prostate cancer	3.14e-05	0.000196	CcSEcCtD
Levomilnacipran—Tachycardia—Doxorubicin—prostate cancer	3.14e-05	0.000196	CcSEcCtD
Levomilnacipran—Headache—Capecitabine—prostate cancer	3.13e-05	0.000195	CcSEcCtD
Levomilnacipran—Skin disorder—Doxorubicin—prostate cancer	3.13e-05	0.000195	CcSEcCtD
Levomilnacipran—Paraesthesia—Epirubicin—prostate cancer	3.12e-05	0.000195	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Doxorubicin—prostate cancer	3.11e-05	0.000194	CcSEcCtD
Levomilnacipran—Dyspnoea—Epirubicin—prostate cancer	3.1e-05	0.000194	CcSEcCtD
Levomilnacipran—Somnolence—Epirubicin—prostate cancer	3.09e-05	0.000193	CcSEcCtD
Levomilnacipran—Anorexia—Doxorubicin—prostate cancer	3.07e-05	0.000191	CcSEcCtD
Levomilnacipran—Nausea—Docetaxel—prostate cancer	3.06e-05	0.000191	CcSEcCtD
Levomilnacipran—Dyspepsia—Epirubicin—prostate cancer	3.06e-05	0.000191	CcSEcCtD
Levomilnacipran—Diarrhoea—Prednisone—prostate cancer	3.04e-05	0.00019	CcSEcCtD
Levomilnacipran—Decreased appetite—Epirubicin—prostate cancer	3.02e-05	0.000189	CcSEcCtD
Levomilnacipran—Hypotension—Doxorubicin—prostate cancer	3.01e-05	0.000188	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Epirubicin—prostate cancer	3e-05	0.000187	CcSEcCtD
Levomilnacipran—Fatigue—Epirubicin—prostate cancer	3e-05	0.000187	CcSEcCtD
Levomilnacipran—Constipation—Epirubicin—prostate cancer	2.97e-05	0.000186	CcSEcCtD
Levomilnacipran—Nausea—Capecitabine—prostate cancer	2.97e-05	0.000185	CcSEcCtD
Levomilnacipran—Dizziness—Prednisone—prostate cancer	2.94e-05	0.000184	CcSEcCtD
Levomilnacipran—Insomnia—Doxorubicin—prostate cancer	2.91e-05	0.000182	CcSEcCtD
Levomilnacipran—Paraesthesia—Doxorubicin—prostate cancer	2.89e-05	0.00018	CcSEcCtD
Levomilnacipran—Dyspnoea—Doxorubicin—prostate cancer	2.87e-05	0.000179	CcSEcCtD
Levomilnacipran—Somnolence—Doxorubicin—prostate cancer	2.86e-05	0.000179	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Epirubicin—prostate cancer	2.84e-05	0.000177	CcSEcCtD
Levomilnacipran—Dyspepsia—Doxorubicin—prostate cancer	2.83e-05	0.000177	CcSEcCtD
Levomilnacipran—Vomiting—Prednisone—prostate cancer	2.83e-05	0.000176	CcSEcCtD
Levomilnacipran—Rash—Prednisone—prostate cancer	2.8e-05	0.000175	CcSEcCtD
Levomilnacipran—Dermatitis—Prednisone—prostate cancer	2.8e-05	0.000175	CcSEcCtD
Levomilnacipran—Decreased appetite—Doxorubicin—prostate cancer	2.8e-05	0.000175	CcSEcCtD
Levomilnacipran—Headache—Prednisone—prostate cancer	2.79e-05	0.000174	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.78e-05	0.000173	CcSEcCtD
Levomilnacipran—Fatigue—Doxorubicin—prostate cancer	2.77e-05	0.000173	CcSEcCtD
Levomilnacipran—Urticaria—Epirubicin—prostate cancer	2.76e-05	0.000172	CcSEcCtD
Levomilnacipran—Constipation—Doxorubicin—prostate cancer	2.75e-05	0.000172	CcSEcCtD
Levomilnacipran—Abdominal pain—Epirubicin—prostate cancer	2.75e-05	0.000172	CcSEcCtD
Levomilnacipran—Body temperature increased—Epirubicin—prostate cancer	2.75e-05	0.000172	CcSEcCtD
Levomilnacipran—Nausea—Prednisone—prostate cancer	2.64e-05	0.000165	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Doxorubicin—prostate cancer	2.63e-05	0.000164	CcSEcCtD
Levomilnacipran—Hypersensitivity—Epirubicin—prostate cancer	2.56e-05	0.00016	CcSEcCtD
Levomilnacipran—Urticaria—Doxorubicin—prostate cancer	2.56e-05	0.00016	CcSEcCtD
Levomilnacipran—Abdominal pain—Doxorubicin—prostate cancer	2.54e-05	0.000159	CcSEcCtD
Levomilnacipran—Body temperature increased—Doxorubicin—prostate cancer	2.54e-05	0.000159	CcSEcCtD
Levomilnacipran—Asthenia—Epirubicin—prostate cancer	2.5e-05	0.000156	CcSEcCtD
Levomilnacipran—Pruritus—Epirubicin—prostate cancer	2.46e-05	0.000154	CcSEcCtD
Levomilnacipran—Diarrhoea—Epirubicin—prostate cancer	2.38e-05	0.000149	CcSEcCtD
Levomilnacipran—Hypersensitivity—Doxorubicin—prostate cancer	2.37e-05	0.000148	CcSEcCtD
Levomilnacipran—Asthenia—Doxorubicin—prostate cancer	2.31e-05	0.000144	CcSEcCtD
Levomilnacipran—Dizziness—Epirubicin—prostate cancer	2.3e-05	0.000144	CcSEcCtD
Levomilnacipran—Pruritus—Doxorubicin—prostate cancer	2.28e-05	0.000142	CcSEcCtD
Levomilnacipran—Vomiting—Epirubicin—prostate cancer	2.21e-05	0.000138	CcSEcCtD
Levomilnacipran—Diarrhoea—Doxorubicin—prostate cancer	2.2e-05	0.000137	CcSEcCtD
Levomilnacipran—Rash—Epirubicin—prostate cancer	2.19e-05	0.000137	CcSEcCtD
Levomilnacipran—Dermatitis—Epirubicin—prostate cancer	2.19e-05	0.000137	CcSEcCtD
Levomilnacipran—Headache—Epirubicin—prostate cancer	2.18e-05	0.000136	CcSEcCtD
Levomilnacipran—Dizziness—Doxorubicin—prostate cancer	2.13e-05	0.000133	CcSEcCtD
Levomilnacipran—Nausea—Epirubicin—prostate cancer	2.07e-05	0.000129	CcSEcCtD
Levomilnacipran—Vomiting—Doxorubicin—prostate cancer	2.05e-05	0.000128	CcSEcCtD
Levomilnacipran—Rash—Doxorubicin—prostate cancer	2.03e-05	0.000127	CcSEcCtD
Levomilnacipran—Dermatitis—Doxorubicin—prostate cancer	2.03e-05	0.000127	CcSEcCtD
Levomilnacipran—Headache—Doxorubicin—prostate cancer	2.02e-05	0.000126	CcSEcCtD
Levomilnacipran—Nausea—Doxorubicin—prostate cancer	1.91e-05	0.000119	CcSEcCtD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	4.44e-06	4.16e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP17A1—prostate cancer	4.43e-06	4.15e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—SULT2A1—prostate cancer	4.42e-06	4.14e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NCOA3—prostate cancer	4.41e-06	4.13e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	4.37e-06	4.09e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—MED12—prostate cancer	4.34e-06	4.07e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GNG5—prostate cancer	4.31e-06	4.04e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—HPGDS—prostate cancer	4.31e-06	4.03e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HSD17B3—prostate cancer	4.27e-06	4e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ACSL4—prostate cancer	4.27e-06	4e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NCOA2—prostate cancer	4.22e-06	3.95e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—HPGDS—prostate cancer	4.2e-06	3.94e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTT1—prostate cancer	4.18e-06	3.91e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ACHE—prostate cancer	4.18e-06	3.91e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP2C19—prostate cancer	4.18e-06	3.91e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NCOA3—prostate cancer	4.15e-06	3.89e-05	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PIK3CA—prostate cancer	4.14e-06	3.88e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP2A6—prostate cancer	4.13e-06	3.87e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	4.11e-06	3.85e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ARG2—prostate cancer	4.1e-06	3.84e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—UMPS—prostate cancer	4.1e-06	3.84e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PHGDH—prostate cancer	4.1e-06	3.84e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTT1—prostate cancer	4.08e-06	3.82e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ACHE—prostate cancer	4.08e-06	3.82e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP2A6—prostate cancer	4.03e-06	3.77e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—SLC5A5—prostate cancer	4.03e-06	3.77e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—LDHB—prostate cancer	4.02e-06	3.76e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—AKR1C3—prostate cancer	4.02e-06	3.76e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PRKACB—prostate cancer	3.99e-06	3.74e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—HPGDS—prostate cancer	3.96e-06	3.71e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	3.96e-06	3.71e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP17A1—prostate cancer	3.95e-06	3.7e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP3A5—prostate cancer	3.94e-06	3.7e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP2C19—prostate cancer	3.94e-06	3.69e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP2E1—prostate cancer	3.93e-06	3.68e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—AKR1C3—prostate cancer	3.92e-06	3.67e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	3.9e-06	3.65e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PRKACB—prostate cancer	3.9e-06	3.65e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NQO1—prostate cancer	3.89e-06	3.64e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP17A1—prostate cancer	3.86e-06	3.62e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ACHE—prostate cancer	3.84e-06	3.6e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTT1—prostate cancer	3.84e-06	3.6e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—TH—prostate cancer	3.83e-06	3.59e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—CREBBP—prostate cancer	3.82e-06	3.58e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PDHA1—prostate cancer	3.81e-06	3.57e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—UCP3—prostate cancer	3.81e-06	3.57e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTA3—prostate cancer	3.81e-06	3.57e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—TCN2—prostate cancer	3.81e-06	3.57e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	3.81e-06	3.57e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP2A6—prostate cancer	3.8e-06	3.56e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP3A4—prostate cancer	3.79e-06	3.55e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	3.77e-06	3.53e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NCOA2—prostate cancer	3.77e-06	3.53e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP1B1—prostate cancer	3.73e-06	3.49e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—AKR1C3—prostate cancer	3.69e-06	3.46e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NCOA2—prostate cancer	3.68e-06	3.44e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PRKACB—prostate cancer	3.67e-06	3.44e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP17A1—prostate cancer	3.64e-06	3.41e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HSD3B1—prostate cancer	3.63e-06	3.4e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SLC22A3—prostate cancer	3.63e-06	3.4e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GGT1—prostate cancer	3.61e-06	3.38e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—SLC5A5—prostate cancer	3.59e-06	3.37e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NCOA1—prostate cancer	3.56e-06	3.33e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP2E1—prostate cancer	3.51e-06	3.29e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—SLC5A5—prostate cancer	3.51e-06	3.29e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP19A1—prostate cancer	3.5e-06	3.28e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTA4—prostate cancer	3.48e-06	3.26e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—TBXAS1—prostate cancer	3.48e-06	3.26e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NQO1—prostate cancer	3.47e-06	3.25e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NCOA2—prostate cancer	3.46e-06	3.25e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP2E1—prostate cancer	3.43e-06	3.21e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—TH—prostate cancer	3.42e-06	3.2e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	3.4e-06	3.18e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTA2—prostate cancer	3.39e-06	3.18e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NQO1—prostate cancer	3.39e-06	3.17e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP3A4—prostate cancer	3.38e-06	3.17e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—RXRA—prostate cancer	3.38e-06	3.17e-05	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—AKT1—prostate cancer	3.38e-06	3.17e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	3.37e-06	3.15e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SULT1A1—prostate cancer	3.35e-06	3.14e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ABCG5—prostate cancer	3.35e-06	3.14e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—TH—prostate cancer	3.34e-06	3.13e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP1B1—prostate cancer	3.33e-06	3.12e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—SLC5A5—prostate cancer	3.31e-06	3.1e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP3A4—prostate cancer	3.3e-06	3.1e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	3.29e-06	3.08e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTA1—prostate cancer	3.28e-06	3.07e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—COMT—prostate cancer	3.26e-06	3.05e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP1B1—prostate cancer	3.25e-06	3.04e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTP1—prostate cancer	3.24e-06	3.04e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTO1—prostate cancer	3.24e-06	3.03e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NAT2—prostate cancer	3.24e-06	3.03e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HSD3B2—prostate cancer	3.24e-06	3.03e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP2E1—prostate cancer	3.23e-06	3.02e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GGT1—prostate cancer	3.22e-06	3.02e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NQO1—prostate cancer	3.19e-06	2.99e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ITPR1—prostate cancer	3.19e-06	2.99e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NCOA1—prostate cancer	3.17e-06	2.97e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—TH—prostate cancer	3.15e-06	2.95e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GGT1—prostate cancer	3.15e-06	2.95e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.14e-06	2.94e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP19A1—prostate cancer	3.13e-06	2.93e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP3A4—prostate cancer	3.11e-06	2.92e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—LRP2—prostate cancer	3.11e-06	2.91e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP2C18—prostate cancer	3.11e-06	2.91e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PLCB2—prostate cancer	3.11e-06	2.91e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NCOA1—prostate cancer	3.1e-06	2.9e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP1B1—prostate cancer	3.06e-06	2.87e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP19A1—prostate cancer	3.05e-06	2.86e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—P4HB—prostate cancer	3.05e-06	2.85e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—RXRA—prostate cancer	3.02e-06	2.83e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—TYMS—prostate cancer	3.01e-06	2.82e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTM1—prostate cancer	2.98e-06	2.79e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GGT1—prostate cancer	2.96e-06	2.78e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SLC22A1—prostate cancer	2.96e-06	2.78e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—RXRA—prostate cancer	2.95e-06	2.76e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.94e-06	2.75e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—LPL—prostate cancer	2.93e-06	2.74e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NCOA1—prostate cancer	2.92e-06	2.74e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—COMT—prostate cancer	2.91e-06	2.72e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTP1—prostate cancer	2.89e-06	2.71e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SULT2A1—prostate cancer	2.89e-06	2.7e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP19A1—prostate cancer	2.88e-06	2.7e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ITPR1—prostate cancer	2.85e-06	2.67e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—MED12—prostate cancer	2.84e-06	2.66e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—COMT—prostate cancer	2.84e-06	2.66e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTP1—prostate cancer	2.83e-06	2.65e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP1A1—prostate cancer	2.83e-06	2.65e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GNG5—prostate cancer	2.82e-06	2.64e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ERCC2—prostate cancer	2.8e-06	2.63e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.8e-06	2.62e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ITPR1—prostate cancer	2.78e-06	2.6e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—RXRA—prostate cancer	2.78e-06	2.6e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NCOA3—prostate cancer	2.71e-06	2.54e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—TYMS—prostate cancer	2.69e-06	2.52e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—COMT—prostate cancer	2.67e-06	2.51e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTP1—prostate cancer	2.66e-06	2.49e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTM1—prostate cancer	2.66e-06	2.49e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—MTHFR—prostate cancer	2.63e-06	2.47e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—TYMS—prostate cancer	2.63e-06	2.46e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ITPR1—prostate cancer	2.62e-06	2.45e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—LPL—prostate cancer	2.61e-06	2.45e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTM1—prostate cancer	2.6e-06	2.43e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HPGDS—prostate cancer	2.59e-06	2.43e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PPARA—prostate cancer	2.58e-06	2.42e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP2C19—prostate cancer	2.57e-06	2.41e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—LPL—prostate cancer	2.55e-06	2.39e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP1A1—prostate cancer	2.52e-06	2.36e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ACHE—prostate cancer	2.51e-06	2.35e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTT1—prostate cancer	2.51e-06	2.35e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ERCC2—prostate cancer	2.5e-06	2.34e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP2A6—prostate cancer	2.48e-06	2.33e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—TYMS—prostate cancer	2.48e-06	2.32e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP1A1—prostate cancer	2.46e-06	2.31e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTM1—prostate cancer	2.45e-06	2.29e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ERCC2—prostate cancer	2.44e-06	2.29e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CAV1—prostate cancer	2.43e-06	2.28e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—AKR1C3—prostate cancer	2.41e-06	2.26e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PRKACB—prostate cancer	2.4e-06	2.25e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—LPL—prostate cancer	2.4e-06	2.25e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP17A1—prostate cancer	2.38e-06	2.23e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—MTHFR—prostate cancer	2.35e-06	2.2e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.32e-06	2.17e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP1A1—prostate cancer	2.32e-06	2.17e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PPARA—prostate cancer	2.31e-06	2.16e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ERCC2—prostate cancer	2.3e-06	2.16e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—MTHFR—prostate cancer	2.29e-06	2.15e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NCOA2—prostate cancer	2.27e-06	2.12e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PPARA—prostate cancer	2.25e-06	2.11e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CG—prostate cancer	2.21e-06	2.07e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CAV1—prostate cancer	2.17e-06	2.03e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—MTHFR—prostate cancer	2.16e-06	2.03e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SLC5A5—prostate cancer	2.16e-06	2.02e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PPARA—prostate cancer	2.12e-06	1.99e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CAV1—prostate cancer	2.12e-06	1.98e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP2E1—prostate cancer	2.11e-06	1.98e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—INS—prostate cancer	2.09e-06	1.96e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NQO1—prostate cancer	2.09e-06	1.96e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.07e-06	1.94e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—TH—prostate cancer	2.06e-06	1.93e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CREBBP—prostate cancer	2.05e-06	1.92e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP1B1—prostate cancer	2e-06	1.87e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CAV1—prostate cancer	1.99e-06	1.87e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CG—prostate cancer	1.98e-06	1.85e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CD—prostate cancer	1.95e-06	1.82e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GGT1—prostate cancer	1.94e-06	1.82e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CG—prostate cancer	1.93e-06	1.81e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NCOA1—prostate cancer	1.91e-06	1.79e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.88e-06	1.76e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—INS—prostate cancer	1.87e-06	1.75e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NOS3—prostate cancer	1.84e-06	1.72e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CREBBP—prostate cancer	1.83e-06	1.72e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—INS—prostate cancer	1.82e-06	1.71e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CG—prostate cancer	1.82e-06	1.7e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—RXRA—prostate cancer	1.82e-06	1.7e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CREBBP—prostate cancer	1.79e-06	1.67e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—COMT—prostate cancer	1.75e-06	1.64e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTP1—prostate cancer	1.74e-06	1.63e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CD—prostate cancer	1.74e-06	1.63e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—INS—prostate cancer	1.72e-06	1.61e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ITPR1—prostate cancer	1.71e-06	1.6e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CB—prostate cancer	1.7e-06	1.59e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CD—prostate cancer	1.69e-06	1.59e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CREBBP—prostate cancer	1.68e-06	1.58e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PTGS2—prostate cancer	1.68e-06	1.57e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NOS3—prostate cancer	1.64e-06	1.54e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—TYMS—prostate cancer	1.62e-06	1.52e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NOS3—prostate cancer	1.6e-06	1.5e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTM1—prostate cancer	1.6e-06	1.5e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CD—prostate cancer	1.6e-06	1.5e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—LPL—prostate cancer	1.57e-06	1.47e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.52e-06	1.42e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CB—prostate cancer	1.51e-06	1.42e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NOS3—prostate cancer	1.51e-06	1.41e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ERCC2—prostate cancer	1.5e-06	1.41e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PTGS2—prostate cancer	1.5e-06	1.41e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CB—prostate cancer	1.48e-06	1.38e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PTEN—prostate cancer	1.47e-06	1.37e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PTGS2—prostate cancer	1.46e-06	1.37e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—MTHFR—prostate cancer	1.41e-06	1.32e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—EP300—prostate cancer	1.4e-06	1.31e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CB—prostate cancer	1.39e-06	1.3e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PPARA—prostate cancer	1.39e-06	1.3e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PTGS2—prostate cancer	1.38e-06	1.29e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PTEN—prostate cancer	1.31e-06	1.23e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CAV1—prostate cancer	1.3e-06	1.22e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PTEN—prostate cancer	1.28e-06	1.2e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—EP300—prostate cancer	1.25e-06	1.17e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—EP300—prostate cancer	1.22e-06	1.14e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PTEN—prostate cancer	1.2e-06	1.13e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.19e-06	1.11e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—EP300—prostate cancer	1.15e-06	1.07e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—INS—prostate cancer	1.12e-06	1.05e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CREBBP—prostate cancer	1.1e-06	1.03e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.04e-06	9.78e-06	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CA—prostate cancer	1.03e-06	9.68e-06	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NOS3—prostate cancer	9.86e-07	9.24e-06	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CA—prostate cancer	9.23e-07	8.64e-06	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CB—prostate cancer	9.1e-07	8.53e-06	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PTGS2—prostate cancer	9.02e-07	8.45e-06	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CA—prostate cancer	9e-07	8.44e-06	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CA—prostate cancer	8.49e-07	7.95e-06	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—AKT1—prostate cancer	8.44e-07	7.91e-06	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PTEN—prostate cancer	7.86e-07	7.37e-06	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—AKT1—prostate cancer	7.54e-07	7.06e-06	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—EP300—prostate cancer	7.5e-07	7.03e-06	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—AKT1—prostate cancer	7.36e-07	6.89e-06	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—AKT1—prostate cancer	6.93e-07	6.5e-06	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CA—prostate cancer	5.55e-07	5.2e-06	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—AKT1—prostate cancer	4.53e-07	4.25e-06	CbGpPWpGaD
